References
- 1. Rydеn L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary. Diab Vasc Dis Res. 2014;11(3):133-73.
- 2. Hoch E, Rusu V, Schreiber SL, Florez JC, Jacobs SB, Lander ES. Type 2 diabetes-associated variants disrupt function of SLC16A11, a proton-coupled monocarboxylate transporter, through two distinct mechanisms, Faseb J. 2017; 31.
- 3. Cowan J. Overview of Type 2 Diabetes. Essentials of SGLT2 Inhibitors in Diabetes, Springer, 2017.
- 4. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA (1c). Diabetes Care 2003; 26:881–5.
- 5. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414:813–20.
- 6. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106:2067–72.
- 7. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006; 295:1681–7.
- 8. Omotayo EO, Gurtu S, Sulaiman SA, Wahab MSA, Sirajudeen K, Salleh MSM. Hypoglycemic and antioxidant effects of honey supplementation in streptozotocin-induced diabetic rats, Int. J. Vitam. Nutr. Res. 2010; 80(1):74-82.
- 9. Maritim AC, Sanders RA, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol. 2003; 17(1):24-38.10.1002/jbt.10058
- 10. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32:193–203.
- 11. Gupta V, Kalra S. Choosing a gliptin. Indian J Endocrinol Metab. 2011; 15:298–308.
- 12. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab. 2011; 13:7–18.10.1111/j.1463-1326.2010.01306.x
- 13. Blech S, Ludwig-Schwellinger E, Grаfe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos. 2010; 38:667–78.
- 14. Marfella R, Barbieri M, Grella R, Rizzo MR, Nicoletti GF, Paolisso G. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complications 2010; 24:79–83.
- 15. Reed, M.J., Meszaros, K., Entes, L.J., Claypool, M.D., Pinkett, J.G., Gadbois, T.M., and Reaven, G.M. 2000. A new rat model of type 2 diabetes: The fat-fed, streptozotocin-treated rat. Metabolism 49:1390-1394.
- 16. Brondum, E., Nilsson, H., and Aalkjaer, C. 2005. Functional abnormalities in isolated arteries from Goto-Kakizaki and streptozotocin-treated diabetic rat models. Horm. Metab. Res. 37:56-60.
- 17. Auclair C, Voisin E (1985). Nitroblue tetrazolium reduction. In: Greenvvald RA (ed) Handbook of methods for oxygen radical research. CRC Press Une, Boca Raton, pp 123–32.
- 18. Pick E, Keisari Y. A simple colorimetric method for the measurment of hydrogen peroxide produced by cells in culture. J Immunol Methods 1980; 38:161–70.10.1016/0022-1759(80)90340-3
- 19. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite and [15 N] nitrate in biological fluids. Anal Biochem 1982; 26: 131–138.10.1016/0003-2697(82)90118-X
- 20. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95:351–8.
- 21. Aebi H. Catalase in vitro. Methods in Enzymology. 1984; 105: 121-6.
- 22. Beutler E. Superoxide dismutase. In: Beutler E, eds. Red Cell Metabolism. A Manual of Biochemical Methods. Philadelphia, Grune & Stratton:PA; 1984: 83-5.
- 23. Beutler E, Duron O, Kelly BM. Improved method for the determination of blood. Glutathione. J Lab Clin Med. 1963; 61: 882–8.
- 24. Akash MS, Rehman K, Chen S. Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. J Cell Biochem. 2013;114(3):525-31.
- 25. Rehman K, Akash MSH. Mechanism of Generation of Oxidative Stress and Pathophysiology of Type 2 Diabetes Mellitus: How Are They Interlinked? J Cell Biochem. 2017;118(11):3577-85.10.1002/jcb.26097
- 26. Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with under-weight, overweight, and obesity. JAMA. 2007;298(17):2028-37.
- 27. Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia. 2002;45(1):85-96.10.1007/s125-002-8248-z
- 28. Shin CS, Moon BS, Park KS, Kim SY, Park SJ, Chung MH, Lee HK. Serum 8-hydroxy-guanine levels are increased in diabetic patients. Diabetes Care. 2001;24(4):733-7.
- 29. Demircan N, Gurel A, Armutcu F, Unalacak M, Aktunc E, Atmaca H. The evaluation of serum cystatin C, malondialdehyde, and total antioxidant status in patients with metabolic syndrome. Med Sci Monit. 2008;14(2):CR97-101.
- 30. Nowotny K, Jung T, Höhn A, Weber D, Grune T. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules. 2015;5(1):194-222.
- 31. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol.2007;39(1):44-84.10.1016/j.biocel.2006.07.001
- 32. Asmat U, Abad K, Ismail K. Diabetes mellitus and oxidative stress-A concise review. Saudi Pharm J. 2016;24(5):547-53.
- 33. Hopps E, Noto D, Caimi G, Averna MR. A novel component of the metabolic syndrome: the oxidative stress. Nutr Metab Cardiovasc Dis. 2010;20(1):72-7.10.1016/j.numecd.2009.06.00219747805
- 34. Pеrez-Matute P, Zulet MA, Martínez JA. Reactive species and diabetes: counteracting oxidative stress to improve health. Curr Opin Pharmacol. 2009;9(6):771-9.10.1016/j.coph.2009.08.005
- 35. Murakami K, Kondo T, Ohtsuka Y, Fujiwara Y, Shimada M, Kawakami Y. Impairment of glutathione metabolism in erythrocytes from patients with diabetes mellitus. Metabolism. 1989;38(8):753-8.2569661
- 36. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005-12.
- 37. Fisman EZ, Motro M, Tenenbaum A. Non-insulin anti-diabetic therapy in cardiac patients: current problems and future prospects. Adv Cardiol. 2008; 45:154-170.
- 38. Kottenberg E, Thielmann M, Kleinbongard P, Frey UH, Heine T, Jakob H, Heusch G, Peters J. Myocardial protection by remote ischaemic pre-conditioning is abolished in sulphonylurea-treated diabetics undergoing coronary revascularisation. Acta Anaesthesiol Scand. 2014;58(4):453-62.
- 39. Green BD, Flatt PR, Bailey CJ. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diabetes and vascular disease research. 2006; 3(3): 159-65.
- 40. Tatosian DA, Guo Y, Schaeffer AK, Gaibu N, Popa S, Stoch A, Langdon RB, Kauh EA. Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. Diabetes Therapy. 2013; 4(2): 431-42.
- 41. Sherif IO, Al-Shaalan NH. Vildagliptin Attenuates Hepatic Ischemia/Reperfusion Injury via the TLR4/NF-κB Signaling Pathway. Oxid Med Cell Longev. 2018; 2018:3509091.
- 42. El-Kashef DH, Serrya MS. Sitagliptin ameliorates thioacetamide-induced acute liver injury via modulating TLR4/NF-KB signaling pathway in mice. Life Sci. 2019; 228:266-273.
- 43. Kelany ME, Hakami TM, Omar AH, Abdallah MA. Combination of Sitagliptin and Insulin against Type 2 Diabetes Mellitus with Neuropathy in Rats: Neuroprotection and Role of Oxidative and Inflammation Stress. Pharmacology. 2016;98(5-6):242-250.
- 44. Helal MG, Zaki MMAF, Said E. Nephroprotective effect of saxagliptin against gentamicin-induced nephrotoxicity, emphasis on anti-oxidant, anti-inflammatory and anti-apoptic effects. Life Sci. 2018; 208:64-71.
- 45. Liu Y, Zhang Z, Chen R, Sun J, Chen H. Therapeutic effect of saxagliptin in rat models of nonalcoholic fatty liver and type 2 diabetes. Nan Fang Yi Ke Da Xue Xue Bao. 2014;34(6):862-8.24968846
- 46. Refaat R, Sakr A, Salama M, El Sarha A. Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats. Drug Dev Res. 2016;77(6):300-9.